BioSpace News Archive

Today, the U.S. Food and Drug Administration permitted marketing of the PicoAMH Elisa diagnostic test as an aid in the determination of a patient’s menopausal status.

Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced results from its dose escalating Phase IB OVATION I trial evaluating neoadjuvant chemotherapy (NAC) treatment for six cycles and GEN-1 given weekly for a total of eight doses prior to interval debulking surgery in newly diagnosed patients with Stage III/IV ovarian cancer.

Joe Vasquez to assume leadership role for Chubb Global Accident & Health

Genomma Lab Internacional, S.A.B. de C.V. today announced its results for the third quarter ended September 30, 2018.

Cipher Pharmaceuticals Inc. today announced the details of its Q3 2018 financial results conference call on Wednesday, November 7, 2018.

Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP) today announced first dosing of subjects in a Phase 1 clinical trial testing a proprietary intranasal formulation of a tetrahydrocannabinol (“THC”)-rich cannabis oil in healthy volunteers.

IMPATHIQ is pleased to announce that the American Heart Association journal Circulation has recently featured the company’s Heart Pathway point-of-care clinical decision support tool.

Global Healthy Living Foundation asserts that health insurance companies are obligated to pass cost savings to patients resulting from the just-announced price reduction for Repatha (evolocumab, Amgen).

Innovative genomic and proteomic analysis platform for Immuno-Oncology and Immune Profiling Applications

Association for Molecular Pathology (AMP) 2018 Annual Meeting & Expo, taking place October 31 – November 3, 2018 in San Antonio, Texas.